In metastatic melanoma, for instance, the combination of bevacizumab and ipilimumab in a phase I study improved immune cell infiltration and augmented efficacy of CTLA-4 blockade [188], and more importantly, humoral immunity to galectin-1 may contribute to the efficacy of anti-VEGF (bevacizumab) and anti-CTLA-4 (ipilimumab) combination therapy [189], offering an additional therapeutic target linking anti-angiogenesis and ICB. The gene discussed is CTLA4; the disease is metastatic melanoma.